Optimizing resources: low-dose nivolumab combinations in the management of relapsed/refractory #HodgkinLymphoma: rdcu.be/d1yE1

Trainees: I will be at #ASH24 ASH-a-Palooza this friday. I want to meet you and talk about books, movies, music, traveling, sports, family life, Mexico and more. Also, I will try to convince you think outside made up lines on maps and work for #GlobalHematology.

Nice real-world data on the safety and efficacy of low-dose nivolumab from Monterrey 🇲🇽 Similarly high response rates and survival with lower doses of 40-140mg Q2W instead of 240mg in the pivotal CM205 study in this single-center cohort (N=27): tinyurl.com/569krdzb

You are using too much nivolumab in Hodgkin. You can use less and get more bang for your buck. Antonio Vega continues our research line on optimal dosing of immune checkpoint inhibitors now in the first line plus AVD led by Perla Colunga #Lymsm #ASH24 2/4

Come to poster 1665 to know more about our work on how to make the most out of PD-1 inhibitors when in a LMIC with me and Héctor A. Vaquera Thanks to our wonderful mentor. Perla Colunga

I’m so proud of you BloodCellsByAlexia My best friend got the ASH David M. Goldenberg CRTI Award Who run the world? 🌎😜 ASH #ASH24

Star fellow BloodCellsByAlexia from UANL presenting now RIC vs MAC in ALL MRDneg patients #ASH24 #Leusm #BMTsm

Super proud of these two. Though I couldn’t attend #ASH24 in person, I’m happy to have served as a reviewer this year and thrilled to see my team and fellows showcasing our work. See you next year!

I’m thrilled to present our transatlantic #PTCy study #ASH24 No matter which side of the ocean you were on 🇪🇸🇲🇽, reduced doses of PTCy (30 mg/kg/d on D3 & D4) proved to be effective and safe in our adult cohort of HLA-matched peripheral blood stem cell HCT patients

Should we use RIC instead of MAC when the MRD is negative in AML? Don’t miss the chance to come and meet Michelle🩸 to discuss this topic

El INCMNSZ felicita a la Dra. María Roberta Demichelis Gómez por su nombramiento como Jefa del Departamento de Hematología y Oncología.

Proud to be a hematologist trained at the best hospital in Mexico! The best mentors, inspiring people—brilliant, but above all, human! Let’s go for more! Perla Colunga Andres Gomez David Gómez-Almaguer

In Monterrey 🇲🇽 we are ready to start treating patients with CAR-T! What's stopping us? Mexico's sanitary agency for whatever bureaucratic reason 🫣 COFEPRIS David Gómez-Almaguer

The Lancet Haematology addressing the need for accelerating action for women´s equality. #InternationalWomensDay2025

No need for slides! Amazing lectures by Dr. Malpica and Dr. Hun Ju Lee today in Monterrey 🇲🇽 #lymsm

Lymphoma docs are the best hematologists! Had a blast interchanging experiences and learning from our deluxe visits in Monterrey 🤩

Alejandra is one of the brightest mentees I’ve had the pleasure of working with #EBMT25 I’m incredibly proud of you @DeLasFuentes99

This is much needed research! Congrats Héctor A. Vaquera Dr. Luis Villela Perla Colunga

So proud of this team’s incredible work. Héctor A. Vaquera , always committed and truly a rising star in the field of Hematology!

Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin #Lymphoma: A Systematic Review. Read the full article. brnw.ch/21wTgyK #ChildhoodCancer